Please note that this is an on-going project.
Project Description
Our team has identified new anti-Giardia compounds with potent and selective activity against drug sensitive and resistant parasites. These compounds have in vivo activity and behave synergistically when combined with other compounds. The aim of our work is to end treatment refractory giardiasis thereby improving health and well-being on a global scale.
Project Personnel and Beneficiaries
This project is anticipated to improve the health and well-being of individuals globally. Noting that giardiasis impacts the health and well-being of humans and animals globally.
Outcomes to Date
The discovery of novel potent and selective antigiardial compounds that are well-tolerated in animals and effective in animals.
Project Significance
Drug resistance hampers the treatment of giardiasis, the world’s most common gastro-intestinal parasitic disease. On an annual basis ~200 million people develop this disease which impacts child development and the general long-term health of many adults. However, there is no vaccine and available treatment options are failing due to factors including drug resistant parasites. This project aims to develop new more effective treatments for giardiasis that will combat drug resistant parasites.